Apnimed (APMD) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma is the larger company by market cap ($770.2 million vs $758.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | IMMX |
|---|---|---|
| Share price | $18.22 | $9.29 |
| Market cap | $758.51M | $770.17M |
| 1-day change | +1.00% | -2.11% |
| YTD return | — | +81.45% |
| 1-year return | — | +278.09% |
| P/E ratio (TTM) | 2.52 | — |
| EPS (TTM) | $7.22 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.29 | $15.10 |
| 52-week low | $16.12 | $2.31 |
| Distance from 52-week high | -48.37% | -38.48% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +176.23% | +161.57% |
| Average volume | 556.65K | 1.65M |
| Shares outstanding | 41.63M | 82.90M |
| Employees | 81 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
APMD vs IMMX FAQ
Which is bigger, Apnimed or Immix Biopharma?
Immix Biopharma (IMMX) is larger, with a market capitalization of $770.17M compared with $758.51M for Apnimed (APMD).
Are Apnimed and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.